Programmed death receptor ligand-2 (PD-L2) bearing extracellular vesicles as a new biomarker to identify early triple-negative breast cancer patients at high risk for relapse
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Cancer Research and Clinical Oncology"
DOI: 10.1007/s00432-022-03980-9
Abstract: Based on the tumor-promoting features of extracellular vesicles (EV) and PD-L1/2-bearing EV subpopulations (PD-L1/2EV), we evaluated their potential as surrogate markers for disease progression or eligibility criteria for PD-1 immune checkpoint inhibition (ICI) approaches in… read more here.
Keywords: cancer; triple negative; early triple; negative breast ... See more keywords
Neoadjuvant apatinib addition to sintilimab and carboplatin-taxane based chemotherapy in patients with early triple-negative breast cancer: the phase 2 NeoSAC trial
Sign Up to like & getrecommendations! Published in 2025 at "Signal Transduction and Targeted Therapy"
DOI: 10.1038/s41392-025-02137-7
Abstract: We aimed to evaluate the efficacy and safety of adding apatinib, to sintilimab and chemotherapy in the neoadjuvant treatment of early triple-negative breast cancer (TNBC). In the phase 2 NeoSAC trial, patients with early TNBC… read more here.
Keywords: cancer; negative breast; chemotherapy; early triple ... See more keywords
Real-world immune-related adverse events in patients with early triple negative breast cancer who received pembrolizumab.
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2024.42.16_suppl.1099
Abstract: 1099 Background: The addition of pembrolizumab to chemotherapy (KEYNOTE-522 regimen) in high risk early triple negative breast cancer (TNBC) has improved clinical outcomes. However, this treatment can result in immune-related adverse events (irAEs) involving any… read more here.
Keywords: cancer; real world; iraes; early triple ... See more keywords